Chemistry: analytical and immunological testing – Involving iga – igd – ige – or igm
Reexamination Certificate
2005-11-22
2005-11-22
Chan, Christina (Department: 1644)
Chemistry: analytical and immunological testing
Involving iga, igd, ige, or igm
C436S547000, C424S130100, C424S178100, C435S069100
Reexamination Certificate
active
06967106
ABSTRACT:
Pooled human plasma is processed by cold ethanol fractionation to produce purified immunoglobulin G antibodies for intravenous administration. Immunoglobulin A is an unwanted by-product since intravenous administration of immunoglobulin A-containing immunoglobulin G can cause life-threatening anaphylaxis in some people. The present invention is the topical application of immunoglobulin A coupled with J chain, and optionally coupled with secretory component in order to render the immunoglobulin A more physiologically active, for the prevention or treatment of ocular diseases including ocular immune deficiency and infections. Antigen-specific monoclonal immunoglobulin A may be used.
REFERENCES:
patent: 5258177 (1993-11-01), Uemura et al.
patent: 5670626 (1997-09-01), Chang
patent: 5808000 (1998-09-01), Mannhalter et al.
patent: 6019968 (2000-02-01), Platz et al.
patent: 6063905 (2000-05-01), Capra et al.
patent: 6124132 (2000-09-01), Blake
patent: 4 122 784 (1993-01-01), None
patent: 1 068 871 (2001-01-01), None
Murkofsky et al, J Biol Chem 254(23): 12181-12184, 1979.
Michetti et al, Adv Exp Med Biol 310: 183-5, 1991.
Zikan et al, Mol Immunol 23(5): 541-4, May 1986.
Bezares et al. “Prevencion de infecctiones en pacientes con sindromes linfoproliferativos y mieloma por nebulizacion de un concentrado de IgA” Sangre 1997; 42(3):219-222.
Sanchez Avalos et al. “Nebulizaciones con IgA humana en pacientes con hipogammaglobulinemia e infecciones de las vias aereas secundararias a enfermedades linfoproliferativas” Medicina (Buenos Aires) 1995: 55(6):727-729.
Leibel et al. “Method for the isolation of biologically active monomeric immunoglobulin A from a plasma fraction” Journal of Chromatography B, 678 (1996) 173-180.
Document bibliography and abstract, Patent WO 0103727.
Document bibliography and abstract, Patent CS242310.
Berzofsky et al. “Monoclonal Antibodies in Chapter 12, Antigen-Antibody Interactions and Monoclonal Antibodies” pp. 455-465 in Fundamental Immunology, Third Edition, W.E. Paul (ed.), Raven Press, NY 1993.
Cohn et al. “Preparation and Properties of Serum and Plasma Proteins IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids” J. Am. Chem. Soc. 1946, 68:459-475.
Corthesy, “Recombinent Secretory IgA for Immune Intervention Against Mucosal Pathogens” Biochem. Soc. Trans. 1997, 25:471-475.
Crottet et al. “Expression, Purification and Biochemical Characterization of Recombinant Murine Secretory Component, A Novel Tool in Mucosal Immunology” Biochem. J. 1999, 341:299-306.
Fahy et al. “Effect of Aerosolized Anti-IgE (E25) on Airway Responses to Inhaled Allergen in Asthmatic Subjects” Am. J. Respir. Crit. Care Med. 1999, 160:1023-1027.
Fruchtman et al. “Aerosol Administration of Human Gamma Globulin as Prophylaxis Against Influenza Virus Challenge” Clin. Med. 1972 (Sep.), 79:17-20.
Giraudi et al. “Upper Respiratory Infections in Children. Response to Endonasal Administration of IgA” Int. J. Pediatr. Otorhinolarynol. 1997, 39:103-110.
Heikkinen et al. “Intranasally Administered Immunoglobulin for the Prevention of Rhinitis in Children” Pediatr. Infec. Dis. J. 1998, 17:367-372.
Hemmingsson et al. “Nasal Administration of Immunoglobulin as Effective Prophylaxis Against Infections in Elite Cross-Country Skiers” Scand. J. Infect. Dis. 1993, 25:73-75.
Johansen et al. “Recombinant expression of polymeric IgA: incorporation of J chain and secretory component of human origin” Eur. J. Immunol. 1999, 29:1701-1708.
Kohler et al. “Continuous Cultures of Fused Cells Secreting Antibody of Predetermined Specificity” Nature 1975, 256:495-497.
Lindberg et al. “Effect of Treatment with Nasal IgA on the Incidence of Infectious Disease in World-Class Canoeists” Int. J. Sports Med. 1996, 17:235-238.
Lullau et al. “Antigen Binding Properties of Purified Immunoglobulin A Antibodies” J. Biol. Chem. 1996, 271:16300-16309.
Mazanec et al. “Comparison of IgA versus IgG Monoclonal Antibodies for Passive Immunization of the Murine Respiratory Tract” Virus Res. 1992, 23:1-12.
Mazanec et al. “Immunoglobulin A Monoclonal Antibodies Protect Against Sendai Virus” J. Virol. 1987, 61:2624-2626.
Oncley et al. “The Separation of the Antibodies, Isoagglutinins, Prothrombin, Plasminogen and B1-Lipoprotein into Subfractions of Human Plasma” J. Am. Chem. Soc. 1949, 71:541-550.
Outlaw et al. “Mechanisms of Neutralization of Influenza Virus on Mouse Tracheal Epithelial Cells by Mouse Monoclonal Polymeric IgA and Polyclonal IgM Directed Against the Viral Haemaglutinen” J. Gen. Virol. 1990, 71:69-76.
Rimensberger et al. “Clinical Experience with Aerosolized Immunoglobulin Treatment of Respiratory Syncytial Virus Infection in Infants” Pediatr. Infect. Dis. J. 1994, 13:328-330.
Rindisbacher et al. “Production of Human Secretory Component with Dimeric IgA Binding Capacity Using Viral Expression Systems” J. Biol. Chem. 1995, 270:14220-14228.
Strong et al. “Blood Fractionation” pp. 576-602 in Vol. 3, Kirk-Othmer Encyclopedia of Chemical Technology. Second Edition, H.F. Mark et al. (eds.), Interscience Publishers, NY 1963.
Symersky et al. “Expression of the Recombinant Human Immunoglobulin J Chain inEscheria coli” Mol. Immunol. 2000, 37:133-140.
Tamara et al. “Cross-Protection Against Influenza A Virus Infection by Passively Transferred Respiratory Tract IgA Antibodies to Different Haemagglutinen Molecules” Eur. J. Immunol. 1991, 21:1337-1344.
Tamura et al. “Functional Role of Respiratory Tract Haemagglutinen-Specific IgA Antibodies in Protection Against Influenza” Vaccine 1990, 8:479-485.
Taylor et al. “Mechanism of Neutralization of Influenza Virus by Secretory IgA is Different from that of Monomeric IgA or IgG” J. Exp. Med. 1985, 161:198-209.
Weltzin et al. “Intranasal Monoclonal Immunoglobulin A Against Respiratory Syncytial Virus Protects Against Upper and Lower Respiratory Tract Infections in Mice” Antimicrob. Agents Chemother. 1994, 38:2785-2791.
Weltzin et al. “Intranasal Monoclonal IgA Antibody Against Respiratory Syncytial Virus Protects Rhesus Monkeys Against Upper and Lower Respiratory Tract Infection” J. Infect. Dis. 1996, 174:256-261.
Wolff et al. “Generation of Aerosolized Drugs” J. Aerosol Med. 1994, 7:89-106.
Chan Christina
Gifford, Krass, Groh Sprinkle, Anderson & Citkowski, P.C.
Huynh Phoung
LandOfFree
Human medical treatment by aerosol inhalation of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human medical treatment by aerosol inhalation of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human medical treatment by aerosol inhalation of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3500241